Disclosure under Regulation 30 of (LODR) Regulations, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts more than Nifty Microcap 250 and 0.2 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The company informed the BSE that the US FDA has completed its Remote Regulatory Assessment (RRA) and Remote Record Review of its Clinical Pharmacology facility in Balanagar, Hyderabad. The review covered studies conducted between October 17, 2025 and November 6, 2025. This is a follow-up to an earlier disclosure made on November 7, 2025. The Managing Director, Krishna Kishore Kuchipudi, confirmed receipt of the Remote Regulatory Assessment Report from the FDA. The filing does not disclose the outcome or any adverse findings from the report.
Closure of the FDA review removes a key regulatory overhang, but since the contents of the RRA Report are not shared, investors should watch for any further disclosures on adverse observations, if any. A clean report would be positive for the stock, while any 483 observations or warning letter could be negative.